Calcitonin gene-related peptide-mediated pharmacological effects in cardiovascular and gastrointestinal diseases

Calcitonin gene-related peptide (CGRP) is the predominant neurotransmitter located in sensory nerves. This peptide is extensively distributed in central and peripheral tissues. CGRP causes relaxation of cardiovascular smooth muscle cells and confers protection against ischaemic myocardium and cardiac remodeling. The pharmacological effects of nitroglycerine and rutaecarpine have been demonstrated to be associated with an increase in the synthesis and release of CGRP. In the gastrointestinal tissues, CGRP participates in the regulation of gastrointestinal function, and exerts protective effects on gastric mucosa. Rutaecarpine, capsaicin and its derivatives, such as evodiamine, decrease gastric mucosal damage induced by several factors, including increased synthesis and release of CGRP. Taken together, this review focuses on the pharmacological effects of several CGRP related canonical drugs and suggests that synthesis and secretion of CGRP exhibit significant therapeutic effects in the occurrence and development of cardiovascular and gastrointestinal diseases.

Automated summary

CGRP serves as a key neurotransmitter in sensory nerves and plays a crucial role in cardiovascular smooth muscle relaxation, protection against cardiac issues, and regulation of gastrointestinal function. Drugs like nitroglycerine and rutaecarpine have been shown to increase the synthesis and release of CGRP, leading to therapeutic effects in cardiovascular and gastrointestinal diseases.